XLON
ZTF
Market cap288mUSD
Oct 07, Last price
444.00GBP
1D
0.68%
1Q
-0.45%
Jan 2017
77.60%
Name
Zotefoams PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zotefoams plc, established in 1921 and headquartered in Croydon, UK, is a global leader in the manufacturing, distribution, and sale of polyolefin block foams. The company serves markets across the United Kingdom, Continental Europe, North America, and other international regions, structured around its Polyolefin Foams, High-Performance Products, and MuCell Extrusion LLC segments. Its product portfolio encompasses the AZOTE range of polyolefin foams, known by brands such as Plastazote, Evazote, and Supazote. Furthermore, Zotefoams develops high-performance foams under the ZOTEK brand, which are formulated from advanced materials including fluoropolymers, engineering polymers, and specialized elastomers. The company also supplies T-FIT, a sophisticated clean insulation solution vital for pharmaceutical, biotech, and semiconductor cleanroom applications. Beyond its product lines, Zotefoams possesses and licenses the patented MuCell microcellular foam technology, complementing this with the sale of related machinery. These diverse offerings are utilized across a broad spectrum of industries, notably automotive, aerospace, product protection, industrial parts, marine, building and construction, military, and sports and leisure.
Key people
David Burns Stirling
Group Chief Executive Officer, Executive Director · since 2000
Gary Christopher McGrath
Finance Director Designate, Director · since 2015
Non-Executive Director · since 2014
Senior Non-Executive Independent Director · since 2018
Headquarters & legal address
602-3 Salisbury House 29
London, LND EC2M 5SQ
GB
London, LND EC2M 5SQ
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||